Advances in micro/nanodrug delivery systems for the treatment of Helicobacter pylori infection: From diagnosis to eradication
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Helicobacter pylori-related gastroenterology studies · Microbial Metabolites in Food Biotechnology · Drug Solubulity and Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Epidemiology of Helicobacter pylori infection10.1111/hel.12403 ↗
2. Helicobacter pylori Infection10.1056/NEJMcp1710945 ↗
3. Global Prevalence of Helicobacter pylori Infection: systematic Review and Meta-Analysis10.1053/j.gastro.2017.04.022 ↗
4. Editorial: the prevalence of Helicobacter pylori infection worldwide-knowns and unknowns10.1111/apt.14609 ↗
5. Serologic evidence for fecal–oral transmission of Helicobacter pylori10.4269/ajtmh.15-0297 ↗
6. Prevalence of Helicobacter pylori from the oral cavity of Mexican asymptomatic children under 5 years of age through PCR10.1016/j.archoralbio.2016.09.007 ↗
7. Helicobacter pylori and its reservoirs: a correlation with the gastric infection10.4292/wjgpt.v7.i1.126 ↗
8. Multiple and mixed Helicobacter pylori infections: comparison of two epidemiological situations in Tunisia and France, Infection10.1016/j.meegid.2015.10.028 ↗
9. Mixed infections of Helicobacter pylori isolated from patients with gastrointestinal diseases in Taiwan10.1155/2016/7521913 ↗
10. Genomic variability of Helicobacter pylori isolates of gastric regions from two Colombian populations10.3748/wjg.v23.i5.800 ↗
11. A. O'Connor, T. Furuta, J.P. Gisbert, C. O'Morain, Review - Treatment of Helicobacter pylori infection 2020, Helicobacter. 25 Suppl 1 (2020) e12743.10.1111/hel.12743 ↗
12. Pharmacological approach to gastric acid suppression: past, present, and future10.1159/000505204 ↗
13. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype10.1111/apt.13588 ↗
14. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects-a randomised open-label cross-over study10.1111/apt.13325 ↗
15. The safety and effectiveness of vonoprazan-based Helicobacter pylori eradication therapy; a prospective post-marketing surveillance10.1080/14740338.2019.1676722 ↗
16. Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters10.1038/s41564-020-00802-x ↗
17. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization Regions10.1053/j.gastro.2018.07.007 ↗
18. Trends in primary antibiotic resistance in H. pylori strains isolated in Italy between 2009 and 201910.3390/antibiotics9010026 ↗
19. Helicobacter pylori pathogenicity and primary antimicrobial resistance in Northern Spain10.1111/eci.13150 ↗
20. Antimicrobial resistance of Helicobacter pylori in Germany, 2015 to 201810.1016/j.cmi.2019.06.007 ↗
21. Increase in antibiotic resistant Helicobacter pylori in a University Hospital in Japan10.2147/IDR.S196452 ↗
22. Characteristics of Helicobacter pylori antibiotic resistance: data from four different populations10.1186/s13756-019-0632-1 ↗
23. Helicobacter pylori biofilm formation and its potential role in pathogenesis
24. Helicobacter pylori Infection10.1056/NEJMra020542 ↗
25. Antibacterial self-assembled nanodrugs composed of berberine derivatives and rhamnolipids against Helicobacter pylori10.1016/j.jconrel.2020.09.025 ↗
26. A. Neshani, H. Zare, M.R. Akbari Eidgahi, A. Hooshyar Chichaklu, A. Movaqar, K. Ghazvini, Review of antimicrobial peptides with anti-Helicobacter pylori activity, Helicobacter. 24(1) (2019).10.1111/hel.12555 ↗
27. Selective killing of Helicobacter pylori with pH-responsive helix–coil conformation transitionable antimicrobial polypeptides10.1073/pnas.1710408114 ↗
28. Mucus as a barrier to drug delivery -understanding and mimicking the barrier properties10.1111/bcpt.12342 ↗
29. S. Ansari, Y. Yamaoka, Survival ofHelicobacter pylori in gastric acidic territory, Helicobacter. 22(4) (2017).10.1111/hel.12386 ↗
30. Sialic acid-based strategies for the prevention and treatment of Helicobacter pylori infection: emerging trends in food industry
31. Biomaterials for Helicobacter pylori therapy: therapeutic potential and future perspectives10.1080/19490976.2022.2120747 ↗
32. A review on the research progress on non-pharmacological therapy of Helicobacter pylori10.3389/fmicb.2023.1134254 ↗
33. Future Nanotechnology-Based Strategies for Improved Management of Helicobacter pylori Infection
34. Kyoto global consensus report on Helicobacter pylori gastritis10.1136/gutjnl-2015-309252 ↗
35. Cellular evasion strategies of Helicobacter pylori in regulating its intracellular fate10.1016/j.semcdb.2020.01.007 ↗
36. Potential antigen candidates for subunit vaccine development against Helicobacter pylori infection10.1002/jcp.28870 ↗
37. Helicobacter pylori: an up-to-date overview on the virulence and pathogenesis mechanisms10.1007/s42770-021-00675-0 ↗
38. Surviving as a Community: antibiotic Tolerance and Persistence in Bacterial Biofilms10.1016/j.chom.2019.06.002 ↗
39. The biofilm life cycle: expanding the conceptual model of biofilm formation10.1038/s41579-022-00767-0 ↗
40. Clinical relevance of point mutations in the 23S rRNA gene in Helicobacter pylori eradication: a prospective, observational study10.1097/MD.0000000000011835 ↗
41. Design and evaluation of novel pH-sensitive ureido-conjugated chitosan/TPP nanoparticles targeted to Helicobacter pylori10.1016/j.biomaterials.2016.01.045 ↗
42. Nanoparticles for oral delivery: design, evaluation and state-of-the-art10.1016/j.jconrel.2016.06.016 ↗
43. Chitosan: a review on properties, biological activities and recent progress in biomedical applications10.1016/j.reactfunctpolym.2023.105634 ↗
44. Methyl cellulose solutions and gels: fibril formation and gelation properties10.1016/j.progpolymsci.2020.101324 ↗
45. (Poly-cyanoacrylate) nanomedicines for cancer and beyond: lessons learned10.1016/j.jconrel.2021.04.028 ↗
46. Using carbomer-based hydrogels for control the release rate of diclofenac sodium: preparation and in vitro evaluation
47. Differentiated chief cells act as reserve stem cells to generate all lineages of the stomach epithelium10.1016/j.cell.2013.09.008 ↗
48. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues10.1016/j.addr.2008.11.002 ↗
49. Construction and optimization of pH-sensitive nanoparticle delivery system containing PLGA and UCCs-2 for targeted treatment of Helicobacter pylori10.1016/j.colsurfb.2018.01.008 ↗
50. Helicobacter pylori infection: from standard to alternative treatment strategies
51. The in vitro photoinactivation of Helicobacter pylori by a novel LED-based device10.3389/fmicb.2020.00283 ↗
52. Co-delivery of chitosan nanoparticles of 5-aminolevulinic acid and shGBAS for improving photodynamic therapy efficacy in oral squamous cell carcinomas10.1016/j.pdpdt.2021.102218 ↗
53. Clinical factors associated with initial eradication therapy: a retrospective study in China
54. Diagnosis ofHelicobacter pylori infection10.1111/hel.12515 ↗
55. Electrochemical immunosensor for rapid and highly sensitive detection of SARS-CoV-2 antigen in the nasal sample
56. Reduced graphene oxide nanohybrid-assembled microneedles as mini-invasive electrodes for real-time transdermal biosensing10.1002/smll.201804298 ↗
57. Electrochemical sensor and biosensor platforms based on advanced nanomaterials for biological and biomedical applications10.1016/j.bios.2017.12.031 ↗
58. Synergistic effect of 2D material coated Pt nanoparticles with PEDOT polymer on electrode surface interface for a sensitive label free Helicobacter pylori CagA((Ag-Ab)) immunosensing10.1016/j.msec.2019.05.018 ↗
59. Aptamer-superparamagnetic nanoparticles capture coupling siderophore-Fe3+scavenging actuated with carbon dots to confer an "off-on" mechanism for the ultrasensitive detection of Helicobacter pylori10.1016/j.bios.2021.113551 ↗
60. Saxena · 2022
61. Evolution of diagnostic methods for Helicobacter pylori infections: from traditional tests to high technology, advanced sensitivity and discrimination tools
62. The "umbrella of tolerance": nanobodies-armed photothermal lateral flow immunoassay for the detection of staphylococcal enterotoxin B
63. The role of Helicobacter pylori neutrophil-activating protein in the pathogenesis of H. pylori and beyond: from a virulence factor to therapeutic targets and therapeutic agents10.3390/ijms24010091 ↗
64. Preparation of aerogel beads and microspheres based on chitosan and cellulose for drug delivery: a review10.1016/j.ijbiomac.2020.12.214 ↗
65. Design principles of microneedles for drug delivery and sampling applications10.1016/j.mattod.2022.10.025 ↗
66. Microspheres for targeted drug delivery- a review on recent applications
67. PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application10.1080/10717544.2021.1938756 ↗
68. Advances in oral drug delivery10.3389/fphar.2021.618411 ↗
69. Gastrointestinal-resident, shape-changing microdevices extend drug release in vivo10.1126/sciadv.abb4133 ↗
70. An ex vivo model enables systematic investigation of the intestinal absorption and transcytosis of oral particulate nanocarriers
71. Lectin antagonists in infection, immunity, and inflammation10.1016/j.cbpa.2019.07.005 ↗
72. Lectin-conjugated microspheres for eradication of Helicobacter pylori infection and interaction with mucus10.1016/j.ijpharm.2014.04.070 ↗
73. Mucoadhesive gastroretentive microparticulate system for programmed delivery of famotidine and clarithromycin10.1080/02652048.2020.1851787 ↗
74. Development of novel pH-sensitive thiolated chitosan/PMLA nanoparticles for amoxicillin delivery to treat Helicobacter pylori10.1016/j.msec.2017.08.038 ↗
75. Chitosan-alginate microcapsules of amoxicillin for gastric stability and mucoadhesion10.4103/2231-4040.93555 ↗
76. Floating-bioadhesive gastroretentive Caesalpinia pulcherrima-based beads of amoxicillin trihydrate for Helicobacter pylori eradication10.3109/10717544.2014.916766 ↗
77. Overview on gastroretentive drug delivery systems for improving drug bioavailability10.1016/j.ijpharm.2016.05.016 ↗
78. Current state and future perspectives on gastroretentive drug delivery systems10.3390/pharmaceutics11040193 ↗
79. A novel gastric-resident osmotic pump tablet: in vitro and in vivo evaluation10.1016/j.ijpharm.2009.08.043 ↗
80. Superparamagnetic iron oxide-encapsulating polymersome nanocarriers for biofilm eradication10.1016/j.biomaterials.2016.12.011 ↗
81. Sinking-magnetic microparticles prepared by the electrospray method for enhanced gastric antimicrobial delivery10.1021/mp5000339 ↗
82. Progress on utilizing hyperthermia for mitigating bacterial infections10.1080/02656736.2017.1369173 ↗
83. A review of magnet systems for targeted drug delivery10.1016/j.jconrel.2019.03.031 ↗
84. Modification of drug delivery to improve antibiotic targeting to the stomach10.4155/tde.15.35 ↗
85. Formulation of clarithromycin floating microspheres for eradication of Helicobacter pylori10.1016/j.jddst.2017.07.016 ↗
86. Highlighting the impact of chitosan on the development of gastroretentive drug delivery systems10.1016/j.ijbiomac.2020.05.104 ↗
87. Gastroretentive drug delivery systems for the treatment of Helicobacter pylori
88. Hydrogel beads-based nanocomposites in novel drug delivery platforms: recent trends and developments10.1016/j.cis.2020.102316 ↗
89. Helicobacter pylori inactivation and virulence gene damage using a supported sensitiser for photodynamic therapy10.1016/j.ejmech.2013.07.023 ↗
90. Duration of adhesion of swallowed alginates to distal oesophageal mucosa: implications for topical therapy of oesophageal diseases10.1111/apt.15884 ↗
91. Formulation and evaluation of floating mucoadhesive alginate beads for targeting Helicobacter pylori10.1111/jphp.12345 ↗
92. Floating mucoadhesive alginate beads of amoxicillin trihydrate: a facile approach for H. pylori eradication10.1016/j.ijbiomac.2016.05.027 ↗
93. Floating-bioadhesive gastroretentiveCaesalpinia pulcherrima-based beads of amoxicillin trihydrate forHelicobacter pylori eradication10.3109/10717544.2014.916766 ↗
94. Hydrogel: preparation, characterization, and applications: a review10.1016/j.jare.2013.07.006 ↗
95. Highly stretchable porous composite hydrogels with stable conductivity for strain sensing10.1016/j.compscitech.2021.108968 ↗
96. Nanocomposite hydrogels for biomedical applications10.1002/btm2.10315 ↗
97. Epidermal growth factor receptor activation protects gastric epithelial cells from Helicobacter pylori-induced apoptosis10.1053/j.gastro.2008.12.059 ↗
98. Synthesis, characterization, anti-inflammatory and anti-Helicobacter pylori activities of novel benzophenone tetracarboxylimide benzoyl thiourea cross-linked chitosan hydrogels10.1016/j.ijbiomac.2021.04.095 ↗
99. Furazolidone treatment for Helicobacter pylori infection: a systematic review and meta-analysis10.1111/hel.12468 ↗
100. Efficacy of bismuth-based quadruple therapy for eradication of Helicobacter pylori infection based on previous antibiotic exposure: a large-scale prospective, single-center clinical trial in China10.1111/hel.12755 ↗